Acumen Pharmaceuticals, Inc.

ABOS

US00509G2093

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
2.31 ^USD	-2.53%		-4.55%	-39.84%

07-01	Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell Small Cap Comp Value Index	CI
07-01	Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell Small Cap Completeness Index	CI

Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 3000E Value Index

July 30, 2024

Latest news about Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell Small Cap Comp Value Index	06-30	CI
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell Small Cap Completeness Index	06-30	CI
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 3000 Value Index	06-30	CI
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 2000 Index	06-30	CI
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 3000E Index	06-30	CI
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 2500 Value Index	06-30	CI
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 2000 Value Index	06-30	CI
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 2000 Dynamic Index	06-30	CI
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 2500 Index	06-30	CI
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 3000 Index	06-30	CI
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell 3000E Value Index	06-30	CI
Transcript : Acumen Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:55 AM	05-15
Transcript : Acumen Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study	05-08	MT
Acumen Pharmaceuticals, Inc. Announces First Patient Dosed in Altitude-Ad, A Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer?S Disease	05-08	CI
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	04-04	MT
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	04-04	MT
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	04-04	CI
Acumen Pharmaceuticals Files $200 Million Mixed Shelf	03-27	MT
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Transcript : Acumen Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024	03-26
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Acumen Pharmaceuticals, Inc. Presents Sabirnetug Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting	03-08	CI
Acumen Pharmaceuticals, Inc. Appoints James Doherty as Its President and Chief Development Officer	02-01	CI

Chart Acumen Pharmaceuticals, Inc.

Duration

Period

More charts

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimerâs pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.31 USD

Average target price

12.8 USD

Spread / Average Target

+454.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACUMEN PHARMACEUTICALS, INC.	-39.84%	139M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research